1. Oshima,M., Dinchuk,J.E., Kargman,S.L., Oshima,H., Hancock,B., Kwong,E., Trzaskos,J.M., Evans,J.F. and Taketo,M.M. ( 1996 ) Suppression of intestinal polyposis in ApcΔ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell , 87 , 803 –809.
2. Chulada,P.C., Thompson,M.B., Mahler,J.F., Doyle,C.M., Gaul,B.W., Lee,C., Tiano,H.F., Morham,S.G., Smithies,O. and Langenbach,R. ( 2000 ) Genetic disruption of Ptgs-1 , as well as of Ptgs-2 , reduces intestinal tumorigenesis in Min mice. Cancer Res. , 60 , 4705 –4708.
3. Jacoby,R.F., Seibert,K., Cole,C.E., Kelloff,G. and Lubet,R.A. ( 2000 ) The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the Min mouse model of adenomatous polyposis. Cancer Res. , 60 , 5040 –5044.
4. Oshima,M., Murai,N., Kargman,S., Arguello,M., Luk,P., Kwong,E., Taketo,M.M. and Evans,J.F. ( 2001 ) Chemoprevention of intestinal polyposis in the Apc Δ716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res. , 61 , 1733 –1740.
5. Boivin,G.P., Washington,K., Yang,K. et al . ( 2003 ) Pathology of mouse models of intestinal cancer: consensus report and recommendations. Gastroenterology , 124 , 762 –777.